JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB146582

CHIR 98014, ATP-competitive GSK3 inhibitor

Be the first to review this product! Submit a review

|

(1 Publication)

MW 486.3 Da, Purity >98%. Potent, selective ATP-competitive GSK3 inhibitor (IC50 values are 0.58 and 0.65 nM for GSKα and GSKβ respectively). Potently activates the Wnt/β-catenin signaling pathway. CHIR 98014 (ab146582) solution.

View Alternative Names

DKFZp686D0638, GSK-3 alpha, GSK-3 beta, GSK3A_HUMAN, GSK3B_HUMAN, GSK3beta isoform, Glycogen synthase kinase-3 alpha, Glycogen synthase kinase-3 beta, Serine/threonine protein kinase GSK3A, Serine/threonine-protein kinase GSK3B

1 Images
Chemical Structure - CHIR 98014, ATP-competitive GSK3 inhibitor (AB146582)
  • Chemical Structure

Lab

Chemical Structure - CHIR 98014, ATP-competitive GSK3 inhibitor (AB146582)

2D chemical structure image of ab146582, CHIR 98014, ATP-competitive GSK3 inhibitor

Key facts

CAS number

252935-94-7

Purity

>98%

Form

Solid

form

Molecular weight

486.3 Da

Molecular formula

C<sub>2</sub><sub>0</sub>H<sub>1</sub><sub>7</sub>Cl<sub>2</sub>N<sub>9</sub>O<sub>2</sub>

PubChem

53396311

Nature

Synthetic

Solubility

Soluble in DMSO to 5 mM

Biochemical name

6-N-[2-[[4-(2,4-dichlorophenyl)-5-imidazol-1-ylpyrimidin-2-yl]amino]ethyl]-3-nitropyridine-2,6-diamine

Biological description

Potent, selective ATP-competitive GSK3 inhibitor (IC50 values are 0.58 and 0.65 nM for GSKα and GSKβ respectively). Potently activates the Wnt/β-catenin signaling pathway. CHIR 98014 (ab146582) solution.

Canonical smiles

C1=CC(=C(C=C1Cl)Cl)C2=NC(=NC=C2N3C=CN=C3)NCCNC4=NC(=C(C=C4)[N+](=O)[O-])N

InChi

InChI=1S/C20H17Cl2N9O2/c21-12-1-2-13(14(22)9-12)18-16(30-8-7-24-11-30)10-27-20(29-18)26-6-5-25-17-4-3-15(31(32)33)19(23)28-17/h1-4,7-11H,5-6H2,(H3,23,25,28)(H,26,27,29)

InChiKey

MDZCSIDIPDZWKL-UHFFFAOYSA-N

IUPAC Name

6-N-[2-[[4-(2,4-dichlorophenyl)-5-imidazol-1-ylpyrimidin-2-yl]amino]ethyl]-3-nitropyridine-2,6-diamine

Product details

This product is manufactured by BioVision, an Abcam company and was previously called 2595 CHIR-98014. 2595-5 is the same size as the 5 mg size of ab146582.

Properties and storage information

Shipped at conditions
Ambient - Can Ship with Ice
Appropriate long-term storage conditions
-20°C
Storage information
Store under desiccating conditions|The product can be stored for up to 12 months

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

Glycogen synthase kinase 3 beta (GSK3β) and glycogen synthase kinase 3 alpha (GSK3α) are serine/threonine protein kinases involved in various cellular processes. GSK3β weighs approximately 47 kDa while GSK3α is around 51 kDa. These proteins are expressed in various tissues including brain heart and liver. GSK3 isoforms act as key regulators in signaling pathways by phosphorylating target proteins affecting their function and stability. Alternative names for GSK3 include GSK-3β and GSK-3α respectively.
Biological function summary

The kinases play essential roles in cellular functions like glycogen metabolism cell cycle regulation and apoptosis. GSK3 proteins often function as part of larger enzyme complexes influencing cellular responses to external signals. They bind to numerous substrates impacting processes such as glucose homeostasis and neuron function. Dramatic changes in GSK3 activity can disrupt these biological processes highlighting their importance.

Pathways

These kinases are integral components of the Wnt/β-catenin and insulin signaling pathways. In the Wnt pathway GSK3 is involved in β-catenin phosphorylation affecting its degradation and transcriptional activity. In the insulin pathway GSK3 influences glycogen synthesis by phosphorylating and regulating glycogen synthase. Both pathways highlight how GSK3 interacts with other proteins such as adenomatous polyposis coli (APC) and axin to coordinate cellular activities.

GSK3 has links to conditions like Alzheimer's disease and diabetes mellitus. Dysregulation of GSK3 activity is observed in Alzheimer's disease where abnormal GSK3 signaling contributes to tau hyperphosphorylation and neurofibrillary tangle formation. In diabetes altered GSK3 function affects insulin signaling pathways influencing glucose metabolism. GSK3's involvement in these diseases often connects it to proteins like tau in Alzheimer's and insulin receptor substrate 1 (IRS1) in diabetes.

Product protocols

Publications (1)

Recent publications for all applications. Explore the full list and refine your search

Brain research 1690:51-60 PubMed29653082

2018

Inhibition of glycogen synthase kinase-3 reduces extension of the axonal leading process by destabilizing microtubules in cerebellar granule neurons.

Applications

Unspecified application

Species

Unspecified reactive species

Yoshihiro Inami,Mitsuru Omura,Kenta Kubota,Yoshiyuki Konishi
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com